(च) उपर्युक्त सारणी में यथा विनिर्दिष्ट खुदरा या प्रबलता या दोनों के साथ अनुसूचित विनिर्मिति का कोई मौजूदा विनिर्माता औषध मूल्य नियंत्रण आदेश, 2013 के पैरा 2 (1) (यू) के अनुसार कोई नई औषधि को लांच करता है तो ऐसे मौजूदा विनिर्माता की औषध (मूल्य नियंत्रण) आदेश 2013 की अनुसूची–II के अंतर्गत यथा विनिर्दिष्ट फार्म–I में एनपीपीए को ऐसी नई औषधि के पूर्व मूल्य अनुमोदन हेतु आवेदन करना होगा।

(छ) उपर्युक्त अनुसूचित विनिर्मितियों के निर्माता उत्पादन/आयात और बिक्री के सम्बन्ध में औषध (मूल्य नियंत्रण) आदेश, 2013 के अनुसूची II के फॉर्म III को आईपीडीएमएस के माध्यम से भरकर एनपीपीए को हर तिमाही की रिपोर्ट प्रस्तुत करेगा। कोई निर्माता उपर्युक्त अनुसूचित विनिर्मितियों का उत्पादन बन्द करन का इच्छुक हो तो वह इसके सम्बन्ध में के उत्पादन और आयात को बन्द करने की तिथि से छः महीने पहले अनुसूची II के फॉर्म IV में भरकर एनपीपीए को प्रस्तुत करेगा।

(ज) विनिर्माता या विपणन कम्पनी, उपरोक्त कथित सारणी में दर्शाये अधिकतम मूल्य और शर्तों का पालन नहीं करती हैं तो वे आवश्यक वस्तुएँ अधिनियम, 1955 के साथ पठित डीपीसीओ, 2013 के प्रावधानों के अधीन ब्याज सहित अधिप्रभारित राशि को जमा करने के लिए उत्तरदायी होंगे।

(झ) इस आदेश में उपरोक्त सारणी के स्तंभ (2) में की गई तत्स्थानी प्रविष्टि में विनिर्दिष्ट ऐसी विनिर्मितियों के पैकों की अधिकतम कीमत नियत होने के परिणामस्वरुप, अधिकतम या खुदरा मूल्य निर्धारित आदेश यदि कोई हो, जो कि इस आदेश से पूर्व जारी हुए है, उनका स्वतः ही अधिक्रमण हो जाएगा ।

[पीएन/241/109/2023/एफ/फा. न. 8(109)/2023/डी.पी./एनपीपीए-डी.वी.-II]

महावीर सैनी, उप निदेशक (मूल्य निर्धारण)

ORDER

New Delhi, the 24th February, 2023

S.O. 879(E).—In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No SO 1499(E) dated 30th March, 2022 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1	Sodium Valproate	Tablet 200mg	1 Tablet	3.20
2	Sodium Valproate	Modified Release – Tablet 500mg	1 Tablet	8.28
3	Sodium Valproate	Tablet 500mg	1 Tablet	7.24
4	Nifedipine	Tablet 10mg	1 Tablet	1.37
5	Noradrenaline	Injection 2mg/mL	1 ML	17.99
6	Halothane	Liquid for inhalation	1 ML	5.44
7	Cyclosporine	Capsule 50 mg	1 Capsule	49.15
8	Cyclosporine	Capsule 100mg	1 Capsule	91.96
9	Adrenaline	Injection1mg/mL	1 ML	10.91

Sl. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
10	Morphine	Injection 10mg/mL	1 ML	17.48
11	Morphine	Injection 15mg/mL	1 ML	13.32
12	Filgrastim	Injection 300mcg	1 Vial	1034.51
13	Midazolam	Injection 1mg/mL	1 ML	5.28
14	Midazolam	Injection 5mg/mL	1 ML	9.70
15	Erythropoietin	Injection 2000IU/mL	1 ML	490.14
16	Erythropoietin	Injection 10000 IU/mL	1 ML	1756.13
17	Furosemide	Injection 10mg/mL	1 ML	2.67
18	Actinomycin D	Powder for Injection 0.5mg	1 Vial	295.22
19	Calcium folinate	Tablet 15mg	1 Tablet	42.40
20	Glucose	Injection 25%	1 ML	0.18
21	Iron sucrose	Injection 20mg/mL	1 ML	51.20
22	Fluphenazine	Injection 25mg/mL	1 ML	49.29
23	Hydroxy propylmethyl cellulose	Injection 2%	1 ML	26.05
24	Alprostadil	Injection 0.5mg/mL	1 ML	5446.23
25	Cisplatin	Injection 1mg/mL	1 ML	6.32
26	Prednisolone	Drops 1%	1 ML	5.14
27	Meglumine diatrizoate	Injection 60%w/v	1 ML	8.45
28	Meglumine diatrizoate	Injection 76%w/v	1 ML	9.10
29	Thiamine	Injection 100 mg/mL	1 ML	20.15
30	Carboplatin	Injection 10mg/mL	1 ML	52.68
31	Gentamicin	Injection 10mg/mL	1 ML	2.15
32	Magnesium sulphate	Injection 500mg/mL	1 ML	4.34
33	Trihexyphenidyl	Tablet 2mg	1 Tablet	1.22
34	Atropine	Drops 1%	1 ML	3.51
35	Atropine	Ointment 1%	1 GM	4.20
36	Atropine	Injection 0.6mg/mL	1 ML	4.08
37	Lignocaine	Topical forms 2-5 %	1 GM/ML	1.01
38	Lignocaine	Injection 2%	1 ML	0.93
39	Povidone iodine	Solution 5%	1 ML	0.39
40	Povidone iodine	Solution 7.5%	1 ML	0.73
41	Povidone iodine	Solution 10% (	1 ML	0.86
42	Sodium Valproate	Modified Release – Tablet 300mg	1 Tablet	5.44
43	Sodium Valproate	Injection 100mg/mL	1 ML	6.02
44	Metoclopramide	Injection 5mg/mL (Less than 10ML Pack)	1 ML	2.38
45	Betamethasone valerate	Cream 0.05%	1 GM	0.60
46	Betamethasone valerate	Cream 0.1%	1 GM	0.93

Sl. No.	Name of the Scheduled Formulation	Dosage form and strength	Unit	Ceiling Price (Rs.)
47	Protamine Sulphate	Injection 10mg/mL	1 ML	8.72
48	Fusidic acid	Cream 2 %	1 GM	8.77
49	Propofol	Injection 10mg/mL	1 ML	5.80
50	Pilocarpine	Drops 2 %	1 ML	9.66
51	Dinoprostone	Gel 0.5mg	1 GM	75.56
52	Tiotropium	Inhalation (MDI) 9 mcg/dose	1 MD	2.48
53	Tiotropium	Inhalation (DPI) 18mcg/dose	1 DP	9.55
54	Ciprofloxacin	Ointment 0.3%	1 GM	1.15
55	Benzoyl peroxide	Gel 2.5	1 GM	3.23
56	Benzoyl peroxide	Gel 5 %	1 GM	7.11
57	Ispaghula	Granules/Husk/Powder	1 GM	0.84
58	Insulin Intermediate Acting (NPH)	Injection 40IU/mL	1 ML	15.15
59	Potassium chloride	Injection 150mg/mL	1 ML	2.14
60	Rifampicin	Oral liquid 100mg/5mL(p)	1 ML	0.42
61	Rabies vaccine	As licensed	1 Vial	337.75
62	Salicylic acid	Ointment 3-6% (6%)	1 GM	1.80
63	Acyclovir	Ointment 3%	1 GM	10.41
64	Phytomenadione (Vitamin K1)	Injection 10mg/mL	1 ML	47.35
65	Human chorionic gonado tropin	Injection 5000 IU	1 Vial	372.32
66	Levothyroxine	Tablet 12.5mcg	1 Tablet	1.32
67	Levothyroxine	Tablet 100mcg	1 Tablet	1.18
68	Levothyroxine	Tablet 125mcg	1 Tablet	1.51
69	Diethylcarbamazine (DEC)	Tablet 50mg	1 Tablet	0.50
70	Isosorbide dinitrate	Tablet 10mg	1 Tablet	0.72
71	Levodopa (A) +Carbidopa(B)	Modified Release–Tablet 100 mg (A) + 25 mg (B)	1 Tablet	2.49
72	Pyrazinamide	Tablet 1500mg	1 Tablet	10.53
73	Phenobarbitone	Oral liquid 20mg/5mL (p)	1 ML	0.44
74	Hydrocortisone	Tablet 10mg	1 Tablet	5.98
75	Neostigmine	Tablet 15mg	1 Tablet	4.09
76	Diethylcarbamazine (DEC)	Oral liquid 120mg/5mL(p)	1 ML	0.43
77	Hydrocortisone	Powder for Injection 200mg	1 Vial	58.51
78	Hydrocortisone	Tablet 5mg	1 Tablet	2.78
79	Hormone Releasing IUD	Contains 52 mg of Levonorgestrel	1 IUD	3456.44
80	IUD containing Copper	As licensed	1 IUD	250.62

Note:

(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

[PN/241/109/2023/F/F. No. 8(109)/2023/D.P./NPPA-Div.-II]

MAHAVEER SAINI, Dy. Director (Pricing)

आदेश

नई दिल्ली, 24 फरवरी, 2023

का.आ. 880(अ).—भारत सरकार के रसायन और उर्वरक मंत्रालय द्वारा जारी का0 आ0 1394(अ) तारीख 30 मई, 2013 और का.आ. 5249(अ) तारीख 11 नवम्बर, 2022 के साथ पठित औषध (कीमत नियंत्रण) आदेश, 2013 के पैरा 4, 6, 10, 11, 14, 16, 17 और 18 द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए तथा भारत सरकार के रसायन एवं उर्वरक मंत्रालय, राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण (जिसको संक्षिप्त रूप में एनपीपीए कहा जाता है), नीचे की सारणी के स्तंभ (5) में विनिर्दिष्ट अधिकतम कीमत को उक्त सारणी के स्तंभ (3) और (4) में क्रमशः